- Home
- MDCX vs GDTC Comparison
MDCX vs GDTC Comparison
Compare MDCX & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MDCX | GDTC |
|---|---|---|
| Founded | 2008 | 2018 |
| Country | United States | Singapore |
| Employees | 12 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.2M | 12.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MDCX | GDTC |
|---|---|---|
| Price | $0.50 | $1.04 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $23.50 | N/A |
| AVG Volume (30 Days) | ★ 8.6M | 13.3K |
| Earning Date | 05-11-2026 | 04-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $5.37 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.37 | $0.73 |
| 52 Week High | $8.90 | $3.68 |
Technical Indicators
Market Signals| Indicator | MDCX | GDTC |
|---|---|---|
| Relative Strength Index (RSI) | 31.61 | 47.35 |
| Support Level | $0.37 | $0.96 |
| Resistance Level | $1.43 | $1.25 |
| Average True Range (ATR) | 0.11 | 0.06 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 15.38 | 51.99 |
Price Performance
Historical ComparisonAbout MDCX Medicus Pharma Ltd.
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.